Companies
Viatris
PharmaceuticalsCanonsburg, PennsylvaniaVTRSMore than 30,000 employees
More about Viatris
Drugmaker that sells generic, branded and off-patent medicines in more than 165 countries
Revenue
$14.3B
Fiscal 2025, down 3%
Employees
More than 30,000
As of December 2025
Stock
VTRS
Nasdaq
Headquarters
Canonsburg, Pennsylvania
CEO
Scott A. Smith
Since April 2023
BrandsLipitor, Norvasc, Viagra, EpiPen, generics
Current strategyRestructuring after a strategic review to build a more focused, efficient company, while fixing FDA issues at its Indore, India plant
Recent workforce changesAbout 10% of its workforce to be cut over three years, announced February 2026
CompetitorsTeva, Sandoz, Hikma
Related companiesPfizerJohnson & Johnson
Checked October 11, 2026 · Sources: sec.gov, manufacturingchemist.com, biospace.com
No source-backed updates for Viatris yet. They appear here when a public report or filing covers the company.
No one has posted about Viatris yet. Be the first to post ›
Follow Viatris in a feed reader, no account needed: RSS feed